Article Sidebar

PDF (Tiếng Việt)
Published: 2023-06-20
Abstract Views: 216
Views PDF (Tiếng Việt): 188
DOI: https://doi.org/10.52852/tcncyh.v167i6.1665
Issue
Vol. 167 No. 6 (2023)
Section
Các bài báo
How to Cite
Lộc, P. Q., Vân, H. T. H., Hương, Đặng T., Quang, N. N., & Giang, L. M. (2023). 33. SARS-CoV-2 Vaccine Breakthrough Infections in Bac Ninh Province, Vietnam, in 2021. Journal of Medical Research, 167(6), 283-295. https://doi.org/10.52852/tcncyh.v167i6.1665

33. SARS-CoV-2 Vaccine Breakthrough Infections in Bac Ninh Province, Vietnam, in 2021

Pham Quang Loc, Hoang Thi Hai Van, Dang Thi Huong, Nguyen Ngo Quang, Le Minh Giang

Main Article Content

Abstract

The study aims to report the prevalence of SARS-CoV-2 vaccine breakthrough infections in Bac Ninh province and evaluate factors associated with the breakthrough infection proportion. Exiting data, retrieved from the immunization management system and the case management system in Bac Ninh province in 2021, were systematically processed and merged. SARS-CoV-2 vaccine breakthrough infections was defined as people with positive RT-PCR result for SARS-CoV-2 before December 28, 2021 and successfully linked with vaccination data. COVID-19 vaccine was enumerated when the date of vaccination at least 14 days before the date of confirmation of SARS-CoV-2 infection. There were 302,407 people vaccinated in Que Vo and Tien Du in 2021; among the vaccinated, 1,324 were infected with SARS-CoV-2, accounting for 0.44% (95%CI: 0.41% - 0.46 %). Younger age, female, and prolonged interval between doses were associated with an increased risk of breakthrough infection. Two or more doses and heterologous doses were associated with a reduced risk of breakthrough infection. SARS-CoV-2 vaccine breakthrough infections was low. Any COVID-19 vaccines are associated with a reduced risk of the infection so it is recommended to maintain vaccination and to adjust the time between doses for optimal effectiveness.

Article Details

Keywords

COVID-19, vaccine, breakthrough infection

References

1. WHO. WHO Coronavirus (COVID1-9) Dashboard. Truy cập ngày 11/04/2023. https://covid19.who.int/.
2. WHO. COVID-19 vaccine tracker and landscape. Truy cập ngày 22/02/2023. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
3. Voysey M, Clemens SA, Madhi SA, Weckx LY, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021; 397(10269): 99-111. https://doi.org/10.1016/S0140-6736(20)32661-1.
4. Polack FP, Thomas SJ, Kitchin N, Absalon J, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020; 383(27): 2603-15. https://doi.org/10.1056/NEJMoa2034577.
5. Bergwerk M, Gonen T, Lustig Y, Amit S, et al. COVID-19 breakthrough infections in vaccinated health care workers. New England Journal of Medicine. 2021; 385(16): 1474-84. https://doi.org/10.1056/NEJMoa2109072.
6. Gupta N, Kaur H, Yadav PD, Mukhopadhyay L, et al. Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India. Viruses. 2021; 13(9): 1782. https://doi.org/10.3390/v13091782.
7. Rovida F, Cassaniti I, Paolucci S, Percivalle E, et al. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nature communications. 2021; 12(1): 6032. https://doi.org/10.1038/s41467-021-26154-6.
8. Hacisuleyman E, Hale C, Saito Y, Blachere NE, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. New England Journal of Medicine. 2021; 384(23): 2212-8. https://doi.org/10.1056/NEJMoa2105000
9. Geysels D, Van Damme P, Verstrepen W, Bruynseels P, et al. SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network. Infection Control & Hospital Epidemiology. 2022; 43(11): 1755-7. https://doi.org/ 10.1017/ice.2021.326.
10. Thompson MG, Burgess JL, Naleway AL, Tyner H, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. New England Journal of Medicine. 2021; 385(4): 320-9. https://doi.org/10.1056/NEJMoa2107058.
11. Dagan N, Barda N, Kepten E, Miron O, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine. 2021; 384: 1412-1423. https://doi.org/10.1056/NEJMoa2101765.
12. Korosec CS, Farhang-Sardroodi S, Dick DW, Gholami S, et al. Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age, and sex. Scientific Reports. 2022; 12(1): 21232. https://doi.org/10.1038/s41598-022-25134-0.
13. WHO. Strategy to achieve global COVID-19 vaccination by mid-2022. Geneva: World Health Organization. (2021). https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf.
14. WHO. SAGE updates COVID-19 vaccination guidance. Truy cập ngày 05/05/2023. https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance.
15. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. New England Journal of Medicine. 2021; 385(24): e83. https://doi.org/10.1056/NEJMoa2114114.
16. Sapkota B, Saud B, Shrestha R, Al-Fahad D, et al. Heterologous prime–boost strategies for COVID-19 vaccines. Journal of Travel Medicine. 2022; 29(3): taab191. https://doi.org/10.1093/jtm/taab191.
17. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature medicine. 2021; 27(9): 1525-9. https://doi.org/10.1038/s41591-021-01449-9.